Search Results 341-350 of 17306 for Teratogenic

  1. A Study to Assess Markers of Aging Process - Mayo Clinic

    The purose of this study is to develop assays to identify markers related to aging processes in a variety of biospecimens, including but limited to blood, urine ...

  2. A Study to Evaluate Pembrolizumab with Standard Therapy to Treat Newly-diagnosed Glioblastoma - Mayo Clinic

    Any of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn ...

  3. My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors - Mayo Clinic

    This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors ...

  4. Clinical Trial of the ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Recurrent Brain Tumors

    ... teratogenic effects of which on the developing fetus and newborn are unknown: * Pregnant persons * Nursing persons * Persons of childbearing potential and ...

  5. Study of Potential VCA Candidates', Caregivers' and Providers' Motivations, Expectations and Shared Decision-making in VCA - Mayo Clinic

    About this study. The purpose of this study is to determine, through in-depth interviews, the motivations, values, preferences, and expectations of VCA ...

  6. First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors - Mayo Clinic

    TP-0903 is a novel oral inhibitor that targets AXL kinase. Preclinical studies have shown promising antitumor activity of TP-0903 as a single agent against a ...

  7. I-124 evuzamitide PET/CT Imaging for the Diagnosis of Cardiac Amyloidosis - Mayo Clinic

    Inclusion Criteria: Understands the study procedures and can give signed informed consent (as specified in Section 10.1.3), which includes compliance with ...

  9. Olaparib and Atezolizumab Either Alone or in Combination in Treating Patients With Stage III-IV Triple Negative Breast Cancer - Mayo Clinic

    Pregnant women are excluded from this study because olaparib and atezolizumab are have the potential for teratogenic or abortifacient effects. Because there ...

  10. A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of Pegcetacoplan in Patients With TA-TMA After Hematopoietic Stem Cell Transplantation (HSCT) - Mayo Clinic

    A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of Pegcetacoplan in Patients With TA-TMA After Hematopoietic Stem Cell Transplantation ( ...